PEDEMONTE, NICOLETTA
PEDEMONTE, NICOLETTA
Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators
2023-01-01 Terlizzi, V.; Pesce, E.; Capurro, V.; Tomati, V.; Lena, M.; Pastorino, C.; Bocciardi, R.; Zara, F.; Centrone, C.; Taccetti, G.; Castellani, C.; Pedemonte, N.
Comprehensive analysis of combinatorial pharmacological treatments to correct nonsense mutations in the cftr gene
2021-01-01 Venturini, A.; Borrelli, A.; Musante, I.; Scudieri, P.; Capurro, V.; Renda, M.; Pedemonte, N.; Galietta, L. J. V.
Cyclic diacyl thioureas enhance activity of corrector Lumacaftor on F508del‐CFTR
2024-01-01 Spallarossa, Andrea; Pedemonte, Nicoletta; Pesce, Emanuela; Millo, Enrico; Cichero, Elena; Rosano, Camillo; Lusardi, Matteo; Iervasi, Erika; Ponassi, Marco
Genotype-phenotype correlations and disease mechanisms in PEX13-related Zellweger spectrum disorders
2022-01-01 Borgia, Paola; Baldassari, Simona; Pedemonte, Nicoletta; Alkhunaizi, Ebba; D'Onofrio, Gianluca; Tortora, Domenico; Calì, Elisa; Scudieri, Paolo; Balagura, Ganna; Musante, Ilaria; Diana, Maria Cristina; Pedemonte, Marina; Vari, Maria Stella; Iacomino, Michele; Riva, Antonella; Chimenz, Roberto; Mangano, Giuseppe D; Mohammadi, Mohammad Hasan; Toosi, Mehran Beiraghi; Ashrafzadeh, Farah; Imannezhad, Shima; Karimiani, Ehsan Ghayoor; Accogli, Andrea; Schiaffino, Maria Cristina; Maghnie, Mohamad; Soler, Miguel Angel; Echiverri, Karl; Abrams, Charles K; Striano, Pasquale; Fortuna, Sara; Maroofian, Reza; Houlden, Henry; Zara, Federico; Fiorillo, Chiara; Salpietro, Vincenzo
Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays
2022-01-01 Parodi, Alice; Righetti, Giada; Pesce, Emanuela; Salis, Annalisa; Tomati, Valeria; Pastorino, Cristina; Tasso, Bruno; Benvenuti, Mirko; Damonte, Gianluca; Pedemonte, Nicoletta; Cichero, Elena; Millo, Enrico
LEAD OPTIMIZATION OF MKT-077 ANALOGUES AS HSP70 ALLOSTERIC INHIBITORS COMBINED WITH F508DEL CFTR CORRECTORS: A MULTI DRUG APPROACH TO CONTRAST CYSTIC FIBROSIS
2024-01-01 Lunaccio, Dario; Garrone, Irene; Pesce, Emanuela; Caushi, Bujar; Salis, Annalisa; Pedemonte, Nicoletta; Sturla, Laura; Bruzzone, Santina; Cichero, Elena; Millo, Enrico
Neutrophil Extracellular Traps in Systemic Lupus Erythematosus Stimulate IgG2 Production From B Lymphocytes
2021-01-01 Bertelli, R.; Schena, F.; Antonini, F.; Reverberi, D.; Signa, S.; Pedemonte, N.; Consolaro, A.; Gattorno, M.; Negrini, S.; Pupo, F.; Volpi, S.; Ghiggeri, G. M.
Partial rescue of f508del-cftr stability and trafficking defects by double corrector treatment
2021-01-01 Capurro, V.; Tomati, V.; Sondo, E.; Renda, M.; Borrelli, A.; Pastorino, C.; Guidone, D.; Venturini, A.; Giraudo, A.; Bertozzi, S. M.; Musante, I.; Bertozzi, F.; Bandiera, T.; Zara, F.; Galietta, L. J. V.; Pedemonte, N.
Patient's dermal fibroblasts as disease markers for visceral myopathy
2023-01-01 Viti, Federica; Pramotton, Francesca Micaela; Martufi, Michela; Magrassi, Raffaella; Pedemonte, Nicoletta; Nizzari, Mario; Zanacchi, Francesca Cella; De Michele, Benedetta; Alampi, Manuela; Zambito, Martina; Santamaria, Giuseppe; Bajetto, Adriana; Sardar, Sabah; Tomati, Valeria; Gandullia, Paolo; Giampietro, Costanza; Florio, Tullio; Beltrame, Francesco; Vassalli, Massimo; Ceccherini, Isabella
Probing Allosteric Hsp70 Inhibitors by Molecular Modelling Studies to Expedite the Development of Novel Combined F508del CFTR Modulators
2021-01-01 Sabbadini, Roberto; Pesce, Emanuela; Parodi, Alice; Mustorgi, Eleonora; Bruzzone, Santina; Pedemonte, Nicoletta; Casale, Monica; Millo, Enrico; Cichero, Elena
Quantification of Ivacaftor, Tezacaftor and Elexacaftor in plasma of cystic fibrosis patients treated with Kaftrio by a validated liquid chromatography-tandem mass spectrometric (LC-MS/MS) method”
2022-01-01 Cafaro, A.; Pigliasco, F.; Barco, S.; Stella, M.; Pedemonte, N.; Cresta, F.; Casciaro, R.; Castellani, C.; Cangemi, G.; Mattioli, F.
QUANTIFICATION OF IVACAFTOR, TEZACAFTOR, AND ELEXACAFTOR IN PLASMA OF CYSTIC FIBROSIS PATIENTS BY AN HPLC–MS/MS METHOD
2023-01-01 Pigliasco, F.; Cafaro, A.; Stella, M.; Baiardi, G.; Barco, S.; Pedemonte, N.; D'Orsi, C.; Cresta, F.; Casciaro, R.; Castellani, C.; Calevo, M. G.; Cangemi, G.; Mattioli, F.
Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background
2023-01-01 Tomati, Valeria; Costa, Stefano; Capurro, Valeria; Pesce, Emanuela; Pastorino, Cristina; Lena, Mariateresa; Sondo, Elvira; Di Duca, Marco; Cresta, Federico; Cristadoro, Simona; Zara, Federico; Galietta, Luis J V; Bocciardi, Renata; Castellani, Carlo; Lucanto, Maria Cristina; Pedemonte, Nicoletta
Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients’ Plasma by a Novel LC–MS/MS Method
2023-01-01 Pigliasco, Federica; Cafaro, Alessia; Stella, Manuela; Baiardi, Giammarco; Barco, Sebastiano; Pedemonte, Nicoletta; D'Orsi, Claudia; Cresta, Federico; Casciaro, Rosaria; Castellani, Carlo; Grazia Calevo, Maria; Mattioli, Francesca; Cangemi, Giuliana
Targeting of Ubiquitin E3 Ligase RNF5 as a Novel Therapeutic Strategy in Neuroectodermal Tumors
2022-01-01 Principi, E.; Sondo, E.; Bianchi, G.; Ravera, S.; Morini, M.; Tomati, V.; Pastorino, C.; Zara, F.; Bruno, C.; Eva, A.; Pedemonte, N.; Raffaghello, L.
The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
2022-01-01 Sondo, E.; Cresta, F.; Pastorino, C.; Tomati, V.; Capurro, V.; Pesce, E.; Lena, M.; Iacomino, M.; Baffico, A. M.; Coviello, D.; Bandiera, T.; Zara, F.; Galietta, L. J. V.; Bocciardi, R.; Castellani, C.; Pedemonte, N.
Therapeutic monitoring of Ivacaftor, Tezacaftor and Elexacaftor in patients with cystic fibrosis|Monitoraggio terapeutico di Ivacaftor, Tezacaftor e Elexacaftor in pazienti con fibrosi cistica
2023-01-01 Pigliasco, F.; Barco, S.; Pedemonte, N.; Cresta, F.; Casciaro, R.; Castellani, C.; Barbagallo, L.; Maffia, A.; Cangemi, G.; Cafaro, A.
Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing
2022-01-01 Fossa, P.; Uggeri, M.; Orro, A.; Urbinati, C.; Rondina, A.; Milanesi, M.; Pedemonte, N.; Pesce, E.; Padoan, R.; Ford, R. C.; Meng, X.; Rusnati, M.; D'Ursi, P.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators | 1-gen-2023 | Terlizzi, V.; Pesce, E.; Capurro, V.; Tomati, V.; Lena, M.; Pastorino, C.; Bocciardi, R.; Zara, F.; Centrone, C.; Taccetti, G.; Castellani, C.; Pedemonte, N. | |
| Comprehensive analysis of combinatorial pharmacological treatments to correct nonsense mutations in the cftr gene | 1-gen-2021 | Venturini, A.; Borrelli, A.; Musante, I.; Scudieri, P.; Capurro, V.; Renda, M.; Pedemonte, N.; Galietta, L. J. V. | |
| Cyclic diacyl thioureas enhance activity of corrector Lumacaftor on F508del‐CFTR | 1-gen-2024 | Spallarossa, Andrea; Pedemonte, Nicoletta; Pesce, Emanuela; Millo, Enrico; Cichero, Elena; Rosano, Camillo; Lusardi, Matteo; Iervasi, Erika; Ponassi, Marco | |
| Genotype-phenotype correlations and disease mechanisms in PEX13-related Zellweger spectrum disorders | 1-gen-2022 | Borgia, Paola; Baldassari, Simona; Pedemonte, Nicoletta; Alkhunaizi, Ebba; D'Onofrio, Gianluca; Tortora, Domenico; Calì, Elisa; Scudieri, Paolo; Balagura, Ganna; Musante, Ilaria; Diana, Maria Cristina; Pedemonte, Marina; Vari, Maria Stella; Iacomino, Michele; Riva, Antonella; Chimenz, Roberto; Mangano, Giuseppe D; Mohammadi, Mohammad Hasan; Toosi, Mehran Beiraghi; Ashrafzadeh, Farah; Imannezhad, Shima; Karimiani, Ehsan Ghayoor; Accogli, Andrea; Schiaffino, Maria Cristina; Maghnie, Mohamad; Soler, Miguel Angel; Echiverri, Karl; Abrams, Charles K; Striano, Pasquale; Fortuna, Sara; Maroofian, Reza; Houlden, Henry; Zara, Federico; Fiorillo, Chiara; Salpietro, Vincenzo | |
| Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays | 1-gen-2022 | Parodi, Alice; Righetti, Giada; Pesce, Emanuela; Salis, Annalisa; Tomati, Valeria; Pastorino, Cristina; Tasso, Bruno; Benvenuti, Mirko; Damonte, Gianluca; Pedemonte, Nicoletta; Cichero, Elena; Millo, Enrico | |
| LEAD OPTIMIZATION OF MKT-077 ANALOGUES AS HSP70 ALLOSTERIC INHIBITORS COMBINED WITH F508DEL CFTR CORRECTORS: A MULTI DRUG APPROACH TO CONTRAST CYSTIC FIBROSIS | 1-gen-2024 | Lunaccio, Dario; Garrone, Irene; Pesce, Emanuela; Caushi, Bujar; Salis, Annalisa; Pedemonte, Nicoletta; Sturla, Laura; Bruzzone, Santina; Cichero, Elena; Millo, Enrico | |
| Neutrophil Extracellular Traps in Systemic Lupus Erythematosus Stimulate IgG2 Production From B Lymphocytes | 1-gen-2021 | Bertelli, R.; Schena, F.; Antonini, F.; Reverberi, D.; Signa, S.; Pedemonte, N.; Consolaro, A.; Gattorno, M.; Negrini, S.; Pupo, F.; Volpi, S.; Ghiggeri, G. M. | |
| Partial rescue of f508del-cftr stability and trafficking defects by double corrector treatment | 1-gen-2021 | Capurro, V.; Tomati, V.; Sondo, E.; Renda, M.; Borrelli, A.; Pastorino, C.; Guidone, D.; Venturini, A.; Giraudo, A.; Bertozzi, S. M.; Musante, I.; Bertozzi, F.; Bandiera, T.; Zara, F.; Galietta, L. J. V.; Pedemonte, N. | |
| Patient's dermal fibroblasts as disease markers for visceral myopathy | 1-gen-2023 | Viti, Federica; Pramotton, Francesca Micaela; Martufi, Michela; Magrassi, Raffaella; Pedemonte, Nicoletta; Nizzari, Mario; Zanacchi, Francesca Cella; De Michele, Benedetta; Alampi, Manuela; Zambito, Martina; Santamaria, Giuseppe; Bajetto, Adriana; Sardar, Sabah; Tomati, Valeria; Gandullia, Paolo; Giampietro, Costanza; Florio, Tullio; Beltrame, Francesco; Vassalli, Massimo; Ceccherini, Isabella | |
| Probing Allosteric Hsp70 Inhibitors by Molecular Modelling Studies to Expedite the Development of Novel Combined F508del CFTR Modulators | 1-gen-2021 | Sabbadini, Roberto; Pesce, Emanuela; Parodi, Alice; Mustorgi, Eleonora; Bruzzone, Santina; Pedemonte, Nicoletta; Casale, Monica; Millo, Enrico; Cichero, Elena | |
| Quantification of Ivacaftor, Tezacaftor and Elexacaftor in plasma of cystic fibrosis patients treated with Kaftrio by a validated liquid chromatography-tandem mass spectrometric (LC-MS/MS) method” | 1-gen-2022 | Cafaro, A.; Pigliasco, F.; Barco, S.; Stella, M.; Pedemonte, N.; Cresta, F.; Casciaro, R.; Castellani, C.; Cangemi, G.; Mattioli, F. | |
| QUANTIFICATION OF IVACAFTOR, TEZACAFTOR, AND ELEXACAFTOR IN PLASMA OF CYSTIC FIBROSIS PATIENTS BY AN HPLC–MS/MS METHOD | 1-gen-2023 | Pigliasco, F.; Cafaro, A.; Stella, M.; Baiardi, G.; Barco, S.; Pedemonte, N.; D'Orsi, C.; Cresta, F.; Casciaro, R.; Castellani, C.; Calevo, M. G.; Cangemi, G.; Mattioli, F. | |
| Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background | 1-gen-2023 | Tomati, Valeria; Costa, Stefano; Capurro, Valeria; Pesce, Emanuela; Pastorino, Cristina; Lena, Mariateresa; Sondo, Elvira; Di Duca, Marco; Cresta, Federico; Cristadoro, Simona; Zara, Federico; Galietta, Luis J V; Bocciardi, Renata; Castellani, Carlo; Lucanto, Maria Cristina; Pedemonte, Nicoletta | |
| Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients’ Plasma by a Novel LC–MS/MS Method | 1-gen-2023 | Pigliasco, Federica; Cafaro, Alessia; Stella, Manuela; Baiardi, Giammarco; Barco, Sebastiano; Pedemonte, Nicoletta; D'Orsi, Claudia; Cresta, Federico; Casciaro, Rosaria; Castellani, Carlo; Grazia Calevo, Maria; Mattioli, Francesca; Cangemi, Giuliana | |
| Targeting of Ubiquitin E3 Ligase RNF5 as a Novel Therapeutic Strategy in Neuroectodermal Tumors | 1-gen-2022 | Principi, E.; Sondo, E.; Bianchi, G.; Ravera, S.; Morini, M.; Tomati, V.; Pastorino, C.; Zara, F.; Bruno, C.; Eva, A.; Pedemonte, N.; Raffaghello, L. | |
| The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs | 1-gen-2022 | Sondo, E.; Cresta, F.; Pastorino, C.; Tomati, V.; Capurro, V.; Pesce, E.; Lena, M.; Iacomino, M.; Baffico, A. M.; Coviello, D.; Bandiera, T.; Zara, F.; Galietta, L. J. V.; Bocciardi, R.; Castellani, C.; Pedemonte, N. | |
| Therapeutic monitoring of Ivacaftor, Tezacaftor and Elexacaftor in patients with cystic fibrosis|Monitoraggio terapeutico di Ivacaftor, Tezacaftor e Elexacaftor in pazienti con fibrosi cistica | 1-gen-2023 | Pigliasco, F.; Barco, S.; Pedemonte, N.; Cresta, F.; Casciaro, R.; Castellani, C.; Barbagallo, L.; Maffia, A.; Cangemi, G.; Cafaro, A. | |
| Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing | 1-gen-2022 | Fossa, P.; Uggeri, M.; Orro, A.; Urbinati, C.; Rondina, A.; Milanesi, M.; Pedemonte, N.; Pesce, E.; Padoan, R.; Ford, R. C.; Meng, X.; Rusnati, M.; D'Ursi, P. |